Construction Methods and Latest Applications of Kidney Cancer Organoids

Overview

Journal Oncol Rev

Specialty Oncology

Date 2024 Nov 27

PMID 39600908

Authors

Zhiqiang Li

Yanqiu You

Bingzheng Feng

Jibing Chen

Hongjun Gao

Fujun Li

Affiliations

Soon will be listed here.

Abstract

Renal cell carcinoma (RCC) is one of the deadliest malignant tumors. Despite significant advances in RCC treatment over the past decade, complete remission is rarely achieved. Consequently, there is an urgent need to explore and develop new therapies to improve the survival rates and quality of life for patients. In recent years, the development of tumor organoid technology has attracted widespread attention as it can more accurately simulate the spatial structure and physiological characteristics of tumors within the human body. In this review, we summarize the main methods currently used to construct kidney cancer organoids, as well as their various biological and clinical applications. Furthermore, combining organoids with other technologies, such as co-culture techniques and microfluidic technologies, can further develop organoids and address their limitations, creating more practical models. This approach summarizes the interactions between different tissues or organs during tumor progression. Finally, we also provide an outlook on the construction and application of kidney cancer organoids. These rapidly evolving kidney cancer organoids may soon become a focal point in the development of clinical models and therapeutic research for kidney cancer.

References

van de Wetering M, Francies H, Francis J, Bounova G, Iorio F, Pronk A . Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015; 161(4):933-45. PMC: 6428276. DOI: 10.1016/j.cell.2015.03.053. View

Lue H, Derrick D, Rao S, Van Gaest A, Cheng L, Podolak J . Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma. Cell Rep Med. 2021; 2(5):100267. PMC: 8149375. DOI: 10.1016/j.xcrm.2021.100267. View

Frantz C, Stewart K, Weaver V . The extracellular matrix at a glance. J Cell Sci. 2010; 123(Pt 24):4195-200. PMC: 2995612. DOI: 10.1242/jcs.023820. View

Artegiani B, Hendriks D, Beumer J, Kok R, Zheng X, Joore I . Fast and efficient generation of knock-in human organoids using homology-independent CRISPR-Cas9 precision genome editing. Nat Cell Biol. 2020; 22(3):321-331. DOI: 10.1038/s41556-020-0472-5. View

Zhao H, Jiang E, Shang Z . 3D Co-culture of Cancer-Associated Fibroblast with Oral Cancer Organoids. J Dent Res. 2020; 100(2):201-208. DOI: 10.1177/0022034520956614. View

Huang Y, Niehrs C . Polarized Wnt signaling regulates ectodermal cell fate in Xenopus. Dev Cell. 2014; 29(2):250-7. DOI: 10.1016/j.devcel.2014.03.015. View

Gao D, Vela I, Sboner A, Iaquinta P, Karthaus W, Gopalan A . Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014; 159(1):176-187. PMC: 4237931. DOI: 10.1016/j.cell.2014.08.016. View

Li Y, Gao X, Ni C, Zhao B, Cheng X . The application of patient-derived organoid in the research of lung cancer. Cell Oncol (Dordr). 2023; 46(3):503-519. PMC: 10205850. DOI: 10.1007/s13402-023-00771-3. View

Wang X, Luo Y, Ma Y, Wang P, Yao R . Converging bioprinting and organoids to better recapitulate the tumor microenvironment. Trends Biotechnol. 2023; 42(5):648-663. DOI: 10.1016/j.tibtech.2023.11.006. View

10.

Lobo N, Gedye C, Apostoli A, Brown K, Paterson J, Stickle N . Efficient generation of patient-matched malignant and normal primary cell cultures from clear cell renal cell carcinoma patients: clinically relevant models for research and personalized medicine. BMC Cancer. 2016; 16:485. PMC: 4947293. DOI: 10.1186/s12885-016-2539-z. View

11.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

12.

Fendler A, Bauer D, Busch J, Jung K, Wulf-Goldenberg A, Kunz S . Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients. Nat Commun. 2020; 11(1):929. PMC: 7026425. DOI: 10.1038/s41467-020-14700-7. View

13.

Warmflash A, Sorre B, Etoc F, Siggia E, Brivanlou A . A method to recapitulate early embryonic spatial patterning in human embryonic stem cells. Nat Methods. 2014; 11(8):847-54. PMC: 4341966. DOI: 10.1038/nmeth.3016. View

14.

Fraley S, Feng Y, Giri A, Longmore G, Wirtz D . Dimensional and temporal controls of three-dimensional cell migration by zyxin and binding partners. Nat Commun. 2012; 3:719. PMC: 4380184. DOI: 10.1038/ncomms1711. View

15.

Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T . Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature. 2013; 499(7459):481-4. DOI: 10.1038/nature12271. View

16.

Castellote-Borrell M, Merlina F, Rodriguez A, Guasch J . Biohybrid Hydrogels for Tumoroid Culture. Adv Biol (Weinh). 2023; 7(12):e2300118. DOI: 10.1002/adbi.202300118. View

17.

Hubert C, Rivera M, Spangler L, Wu Q, Mack S, Prager B . A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo. Cancer Res. 2016; 76(8):2465-77. PMC: 4873351. DOI: 10.1158/0008-5472.CAN-15-2402. View

18.

Sato T, Vries R, Snippert H, van de Wetering M, Barker N, Stange D . Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009; 459(7244):262-5. DOI: 10.1038/nature07935. View

19.

Yoshida G . Applications of patient-derived tumor xenograft models and tumor organoids. J Hematol Oncol. 2020; 13(1):4. PMC: 6947974. DOI: 10.1186/s13045-019-0829-z. View

20.

Calandrini C, Schutgens F, Oka R, Margaritis T, Candelli T, Mathijsen L . An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity. Nat Commun. 2020; 11(1):1310. PMC: 7066173. DOI: 10.1038/s41467-020-15155-6. View